Organon: Adalimumab Sales Won’t Surpass $100m In 2023, Despite US Launch
US-Based Firm In ‘Fight’ For Formulary Position, Eyeing Further BD Opportunities
Organon has provided a relatively clear guide for how its planned launch of a US biosimilar to AbbVie’s Humira in July will impact its top line in 2023, with further detail on the coming years.
